Berkeley HeartLab provides cardiovascular disease (CVD) management
tools and services with a distinctive focus on the secondary prevention
market. Unlike other lipid testing companies that are focused on the
primary screening market for CVD, Berkeley's proprietary testing technology
enables risk characterization and uniquely allows for ongoing therapeutic
monitoring of a patient's disease.
These tests help clinicians identify
and stratify risks and recommend treatment for cardiovascular disease
with high levels of confidence. Proven Diagnostics® collaborates with Berkeley HeartLab through our Porfolio of Excellence program to offer KIF-6 genotyping to identify at-risk patients and guide their treatment.
For more information, visit the Berkeley
HeartLab website.